Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 242 across all filing types
Latest filing 2022-01-06 Governance Information
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
Code of conduct.pdf
Governance Information Classification · 95% confidence The document is titled 'Code of Business Conduct and Ethics' and is adopted by the Board of Directors of Marvel Biosciences Corp. It outlines ethical standards, employee responsibilities, compliance with laws, conflicts of interest, confidentiality, and other governance-related policies. There is no financial data, no discussion of financial results, no mention of annual or quarterly reporting, no voting results, no capital changes, no legal proceedings, no merger or acquisition activity, and no executive compensation details. The document is a governance-related policy document detailing internal rules and ethical standards for employees and directors. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains the full text of the code, not just an announcement or summary, so it is not an RPA or RNS. Confidence is high given the clear nature of the document.
2022-01-06 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) and dated December 15, 2021. It references unaudited condensed interim financial statements for the period ended October 31, 2021, and annual audited consolidated financial statements for the year ended July 31, 2021. The content includes detailed discussion of business strategy, product development, scientific background, and future milestones. It contains substantive financial and operational analysis rather than just an announcement or summary. The length is about 15,000 characters, indicating a full report rather than a brief notice. The MD&A is a management report explaining financial results, business trends, and outlook, which fits the definition of Management Reports (MDA). It is not an Annual Report (10-K) or Interim Report (IR) because it references but does not itself contain full financial statements, and the focus is on management discussion. It is not a Regulatory Filing or Report Publication Announcement since it contains detailed analysis and not just a certification or announcement. Therefore, the appropriate classification is Management Reports (MDA).
2021-12-16 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings by the CFO of Marvel Biosciences Corp. It certifies the review and fair presentation of the interim consolidated financial report and interim MD&A for the period ended October 31, 2021. The document is primarily a certification letter and does not contain the actual interim financial statements or substantive financial data. It references the interim filings but does not include them. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3045 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2021-12-16 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification statement by the CEO of Marvel Biosciences Corp. regarding the review and fair presentation of the interim consolidated financial report and interim MD&A for the period ended October 31, 2021. It is a Form 52-109FV2 Certification of Interim Filings, which is an officer attestation confirming the accuracy and completeness of interim filings. The document does not contain actual financial data or substantive financial analysis but is a certification letter. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3063 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2021-12-16 English
Interim financial statements/report – English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice and management information circular for a special meeting of shareholders regarding a statutory plan of arrangement under the Canada Business Corporations Act. It involves a transaction where shareholders are asked to approve an acquisition arrangement. The document includes board recommendations, reasons for the arrangement, fairness opinions, procedural safeguards, and voting instructions. This type of document is typically classified as Proxy Solicitation & Information Statement (PSI) because it is sent to shareholders to provide information and request votes for a meeting concerning a significant corporate transaction. It is not an announcement of voting results (DVA), nor a merger filing (MA) or merger activity announcement (TAR), but rather the solicitation material for the vote. The length and content confirm it is not a brief announcement or a report publication announcement. Therefore, the correct classification is PSI with high confidence.
2021-12-16 English
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a news release announcing the completion of a manufacturing engineering run for a pharmaceutical asset by Marvel Biosciences. It discusses operational progress, future plans for clinical trials, and company background. There are no financial statements, regulatory filings, voting results, or detailed financial data. The document is a corporate press release about operational milestones rather than a formal financial or regulatory report. Therefore, it does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Capital/Financing Update (CAP) because it relates to progress in the company's development pipeline, which is often considered a material update relevant to investors and capital markets.
2021-12-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.